Incretin Atlas › Trials › MARITIME-CV
MARITIME-CV
MariTide · Obesity with established CVD
Design
- Molecule(s)
- MariTide
- Population
- Obesity with established CVD
- Official title
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Sponsor
- Amgen
- Phase
- Phase 3
- Registry status
- active not recruiting · 2025-07 → 2028-06
- Participants
- 12800
- Registry
- NCT07037433
Ongoing outcome trial
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| MARITIME-CV | MariTide | Obesity with established CVD Obesity + established CVD, with or without T2D | MACE | 12800 | recruiting | 2028-06-30 | NCT07037433 |
No results yet; the primary completion date comes from the registry.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: MARITIME-CV. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/maritime-cv/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.